Fiji
Tuberculosis profile
Population  2012 <1 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.015 (0.014–0.015) 1.7 (1.6–1.7)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.02 (0.02–0.03)
Prevalence  (includes HIV+TB) 0.26 (0.088–0.53) 30 (10–61)
Incidence  (includes HIV+TB) 0.21 (0.19–0.24) 24 (21–27)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.15 (0.13–0.17)
Case detection, all forms (%) 99 (87–110)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 111 (54) Relapse 5 (38)
Smear-negative 54 (26) Treatment after failure 1 (8)
Smear-unknown / not done 0 (0) Treatment after default 5 (38)
Extrapulmonary 40 (20) Other 2 (15)
Other 0 (0)      
Total new 205   Total retreatment 13  
           
Other (history unknown) 0        
Total new and relapse 210   Total cases notified 218  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.2 1.3 1.5
Age < 15 4 9 8
Laboratories 2012
Smear (per 100 000 population) 0.5
Culture (per 5 million population) 5.7
Drug susceptibility testing (per 5 million population) 0
Is second-line drug susceptibility testing available? No
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 93   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 89  
Retreatment 57  
TB/HIV 2012 Number (%)
TB patients with known HIV status 127 (58)
HIV-positive TB patients 5 (4)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 5 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 3 (60)
HIV-positive people screened for TB 49  
HIV-positive people provided with IPT 1  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 0 (0–8.2) 0 (0–98)
MDR-TB cases among notified pulmonary
TB cases
0 (0–14) 0 (0–13)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 15 (9%) 1 (8%) 16
Laboratory-confirmed MDR-TB cases 0 0 0
Patients started on MDR-TB treatment     0
Financing TB control 2013
National TB programme budget (US$ millions) 5
% Funded domestically 73%
% Funded internationally 27%
% Unfunded 0%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-24 Data: www.who.int/tb/data